BioMimetic Pharmaceuticals, Inc. to Introduce Augmatrix™ Biocomposite Bone Graft Product Line at American Academy of Orthopaedic Surgeons  
2/8/2012 7:40:24 AM

FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced it will introduce Augmatrix™ Biocomposite Bone Graft, a new bone graft substitute product line, to surgeons and distributors at its exhibit booth during the American Academy of Orthopedic Surgeons (AAOS) meeting this week in San Francisco, CA.